Etiometry Secures FDA Clearance for Cardiogenic Shock Automation Tool
Etiometry, a leader in AI-powered clinical intelligence, has announced a significant milestone with the receipt of clearance from the U.S. Food and Drug Administration (FDA) for its innovative Cardiogenic Shock Tool. This marks the first-ever FDA-cleared solution designed to automate hospital-specific classification and longitudinal tracking of cardiogenic shock using real-time physiologic data.
The clearance (K254066) represents a major advancement in how hospitals detect, classify, and manage one of the most critical cardiovascular emergencies. By leveraging advanced analytics and integrating multiple clinical data sources, Etiometry aims to address longstanding gaps in early detection and coordinated care.
Understanding the Challenge of Cardiogenic Shock
Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body’s needs. Despite advances in cardiovascular care, it remains associated with high mortality rates and poor patient outcomes. One of the primary challenges in managing cardiogenic shock is delayed identification, which often results in missed opportunities for timely intervention.
Studies indicate that up to 50% or more of cardiogenic shock cases go undocumented—even at advanced stages. This underreporting not only delays critical treatment but also impacts hospital quality metrics and reimbursement processes. The complexity of diagnosing and staging shock, combined with fragmented data across systems, has historically made consistent monitoring difficult.
Introducing the Etiometry Cardiogenic Shock Tool
Etiometry’s newly cleared Cardiogenic Shock Tool is designed to tackle these challenges head-on. The solution automates the classification and tracking of cardiogenic shock by directly utilizing high-fidelity physiologic monitoring data.
At its core, the platform integrates:
- Continuous physiologic monitoring data
- Electronic health records (EHRs)
- Laboratory results
- Medical device inputs
This integration enables a unified, real-time view of a patient’s hemodynamic status and organ function. By consolidating these data streams, clinicians gain actionable insights that were previously difficult to obtain in a timely and standardized manner.
Alignment with SCAI Guidelines and Hospital Protocols
A key strength of the tool lies in its alignment with the Society for Cardiovascular Angiography and Interventions (SCAI) cardiogenic shock classification system. The SCAI framework provides a standardized staging model that helps clinicians assess the severity and progression of shock.
Etiometry’s platform applies these guidelines while also adapting to institution-specific protocols. This dual approach ensures that hospitals can maintain consistency with industry standards while tailoring the system to their unique workflows and care pathways.
The result is a scalable, hospital-wide surveillance system that supports:
- Continuous monitoring of shock stages
- Standardized classification across departments
- Improved coordination among multidisciplinary care teams
Real-Time Insights Across the Continuum of Care
One of the most transformative aspects of the Cardiogenic Shock Tool is its ability to provide continuous, longitudinal tracking of patient status across different care settings. From the operating room (OR) and intensive care unit (ICU) to step-down units and telemetry floors, the platform ensures that clinicians have a consistent view of patient progression.
This continuity is critical for managing complex cases where patients transition between multiple departments. The system enables clinicians to:
- Detect early signs of deterioration
- Evaluate response to therapies
- Adjust treatment plans based on standardized data
By delivering a consolidated and dynamic picture of patient health, the tool enhances clinical decision-making and reduces variability in care.
Improving Documentation and Operational Efficiency
Beyond clinical benefits, Etiometry’s solution addresses a significant operational challenge: incomplete or inconsistent documentation of cardiogenic shock. Accurate documentation is essential not only for patient care but also for hospital performance metrics and reimbursement.
The platform’s automated classification capabilities help ensure that shock severity is consistently recorded and tracked over time. This leads to:
- More accurate representation of patient acuity
- Improved quality reporting
- Enhanced reimbursement capture
In addition, the Etiometry Platform has been associated with measurable operational improvements, including:
- Reduced hospital length of stay
- Fewer ICU readmissions
- Shorter durations of critical therapies
These outcomes highlight the broader impact of integrating AI-driven tools into clinical workflows.
Enhancing Clinical Decision Support
According to Shane Cooke, President and CEO of Etiometry, the FDA clearance underscores the company’s commitment to delivering comprehensive decision support solutions for cardiac care.
The Cardiogenic Shock Tool adds a critical layer to Etiometry’s platform by combining shock classification with respiratory and hemodynamic trajectory tracking. This integrated approach provides clinicians with a more complete and timely understanding of patient status.
Rather than relying on fragmented or delayed data, care teams can now access a unified operational picture that supports faster and more informed decisions—especially in high-stakes scenarios involving critically ill patients.
Supporting Clinicians, Not Replacing Them
It is important to note that the Etiometry Cardiogenic Shock Tool is designed as an adjunctive clinical support system. It is not intended to replace clinician judgment or serve as a sole source of decision-making.
The platform:
- Does not function as an alarm system
- Is not intended for active patient monitoring
- Should be used alongside clinical expertise
Instead, it enhances the clinician’s ability to interpret complex data and identify trends that might otherwise go unnoticed.
Advancing the Future of AI in Healthcare
The FDA clearance of Etiometry’s Cardiogenic Shock Tool reflects a broader trend toward the adoption of AI-driven solutions in healthcare. As hospitals increasingly seek to improve outcomes while managing costs, technologies that enable real-time insights and standardized care are becoming essential.
Etiometry continues to expand its portfolio of clinical intelligence tools, focusing on empowering healthcare providers with data-driven insights. By bridging the gap between raw data and actionable information, the company is helping to transform how critical conditions like cardiogenic shock are managed.
Etiometry’s FDA-cleared Cardiogenic Shock Tool represents a significant advancement in cardiovascular care. By automating classification, enabling continuous tracking, and integrating diverse data sources, the platform addresses key challenges in early detection, documentation, and coordinated treatment.
With its alignment to SCAI guidelines and adaptability to hospital protocols, the solution offers a scalable approach to improving both clinical and operational outcomes. As AI continues to reshape healthcare, innovations like this are poised to play a pivotal role in enhancing patient care and saving lives.
About Etiometry
Founded in 2010, Etiometry offers an AI-driven clinical intelligence platform designed to help critical care clinicians make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times.
Etiometry has received 11 FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization.
